辉瑞
PFE
29.58
+0.14
+0.48%
辉瑞
US · PFE
#133 按市值排名
上市于 1970
29.58
+0.14
+0.48%
实时 - 追踪5344个代码 - 心跳于543秒前
· 2026-10-16 20:02
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了6家。
- 机构持股总比例基本持平。
机构持股
- 机构持股比例
- 68.27% +0.05pp
- 机构数量
- 3,245 -6
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund55.48%
Public Company4.59%
Private Company2.79%
Government Pension Fund1.93%
Hedge Fund1.19%
Sovereign Wealth Fund1.15%
VC/PE Fund0.31%
Insurance Company0.30%
Family Office/Trust0.28%
Other31.98%
主要股东 截至 2026-06-30
BlackRock
9.29% · 529.67M 股
Vanguard Capital Management, LLC
7.09% · 404.16M 股
State Street Global Advisors
5.39% · 307.09M 股
Geode Capital Management, LLC
2.37% · 135.28M 股
Vanguard Portfolio Management, LLC
2.09% · 119.24M 股
Other
73.76%
Fisher Investments
1.91% · 109.07M 股
Morgan Stanley
1.20% · 68.22M 股
Norges Bank Investment Management
1.08% · 61.51M 股
Northern Trust Global Investments
1.04% · 59.08M 股
MFS Investment Management
0.99% · 56.55M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 44次买入 · 2次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Albert Bourla | Chairperson & CEO | 0.01% |
| G. Dolsten | Chief Scientific Officer and President of Research & Development | 0.00% |
| Sally Susman | Executive VP & Chief Corporate Affairs Officer | 0.00% |
| Douglas Lankler | Executive Vice President | 0.00% |
| Chris Boshoff | Executive VP and Chief Oncology Research & Development Officer | 0.00% |
| Cecile Guegan | Senior VP & Head of Biopharma Group Finance | 0.00% |
| Michael McDermott | Executive VP & Chief Global Supply Officer | 0.00% |
| Ronald Blaylock | Independent Director | 0.00% |
| Dennis Hancock | Executive Vice President | 0.00% |
| Lidia Fonseca | Executive VP and Chief Digital & Technology Officer | 0.00% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-29 | Albert Bourla | Chairperson & CEO | Other Derivative Acquisition | +21 | -- |
| 2026-09-24 | Shantanu Narayen | Lead Independent Director | Other Derivative Acquisition | +1,743 | -- |
| 2026-09-24 | James Smith | Independent Director | Other Derivative Acquisition | +1,569 | -- |
| 2026-09-24 | Mortimer Buckley | Director | Other Derivative Acquisition | +1,307 | -- |
| 2026-09-24 | James Robert Quincey | Independent Director | Other Derivative Acquisition | +1,351 | -- |
| 2026-09-24 | Cyrus Russi Taraporevala | Director | Other Derivative Acquisition | +1,307 | -- |
| 2026-09-24 | Joseph Echevarria | Independent Director | Other Derivative Acquisition | +1,613 | -- |
| 2026-09-14 | Albert Bourla | Chairperson & CEO | Other Derivative Acquisition | +22 | -- |
| 2026-08-30 | Albert Bourla | Chairperson & CEO | Other Derivative Acquisition | +21 | -- |
| 2026-08-16 | Cecile Guegan | Senior VP & Head of Biopharma Group Finance | Initial Statement of Beneficial | 0 | -- |
| 2026-08-13 | Albert Bourla | Chairperson & CEO | Other Derivative Acquisition | +22 | -- |
| 2026-08-11 | Albert Bourla | Chairperson & CEO | Open Market Acquisition | +38,000 | $26.34 |
| 2026-08-04 | Ronald Blaylock | Independent Director | Open Market Acquisition | +39,231 | $25.46 |
| 2026-08-04 | Mortimer Buckley | Director | Open Market Acquisition | +37,632 | $25.52 |
| 2026-08-04 | Jennifer Damico | Officer | Open Market Disposition | -3,278 | $25.40 |
| 2026-07-30 | Albert Bourla | Chairperson & CEO | Other Derivative Acquisition | +24 | -- |
| 2026-07-14 | Albert Bourla | Chairperson & CEO | Other Derivative Acquisition | +24 | -- |
| 2026-07-08 | Albert Bourla | Chairperson & CEO | Other Derivative Acquisition | +84 | -- |
| 2026-06-29 | Albert Bourla | Chairperson & CEO | Other Derivative Acquisition | +25 | -- |
| 2026-06-25 | Shantanu Narayen | Lead Independent Director | Other Derivative Acquisition | +2,058 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 20:02:09 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
辉瑞 讨论区 0 条评论